Prostate cancer: Psychosocial implications and management

Future Oncology

Volumn 4, Issue 4, 2008, Pages 561-568

  Roth, Andrew J ^a   Weinberger, Mark I ^b   Nelson, Christian J ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

Older adults; Prostate cancer; Psychiatric management; Screening; Treatment

Indexed keywords

AMFEBUTAMONE; ANALGESIC AGENT; BICALUTAMIDE; FLUOXETINE; FLUTAMIDE; GOSERELIN; LEUPRORELIN; METHYLPHENIDATE; MODAFINIL; PAROXETINE; PROSTAGLANDIN E1; PROSTATE SPECIFIC ANTIGEN; SERTRALINE; SILDENAFIL; TADALAFIL; VARDENAFIL; VENLAFAXINE;

ADJUVANT THERAPY; ANEMIA; ANXIETY DISORDER; BRACHYTHERAPY; CANCER PAIN; CANCER RADIOTHERAPY; CANCER SCREENING; COGNITIVE THERAPY; DEPRESSION; DIGITAL RECTAL EXAMINATION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; ERECTILE DYSFUNCTION; FATIGUE; GYNECOMASTIA; HOT FLUSH; HUMAN; IMPOTENCE; LIBIDO DISORDER; MUSCLE ATROPHY; OSTEOPOROSIS; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PSYCHOSOCIAL WITHDRAWAL; PSYCHOTHERAPY; QUALITY OF LIFE; REVIEW; SOCIAL PSYCHOLOGY; URINE INCONTINENCE;

ADENOCARCINOMA; ADULT; AGE FACTORS; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; DISEASE MANAGEMENT; ERECTILE DYSFUNCTION; FATIGUE; FEAR; HUMANS; INTERPERSONAL RELATIONS; MALE; MASS SCREENING; MIDDLE AGED; PAIN; PATIENT ACCEPTANCE OF HEALTH CARE; POSTOPERATIVE COMPLICATIONS; PROSTATECTOMY; PROSTATIC NEOPLASMS; PSYCHOLOGY; PSYCHOTHERAPY; QUALITY OF LIFE; URINARY INCONTINENCE;

EID: 55349107782     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/14796694.4.4.561     Document Type: Review

References (56)

1. American Cancer Society: Cancer Facts and Figures. ACS, CA, USA (2007).
2. Penson DF, Litwin MS: Quality of life after treatment for prostate cancer. Curr. Urol. Rep. 4, 185-195 (2003).
3. Potosky AL, Davis WW, Hoffman RM et al.: Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the Prostate Cancer Outcomes Study. J. Natl Cancer Inst. 96(18), 1358-1367 (2004).
4. Klotz L: Active surveillance with selective delayed intervention is the way to manage 'good risk' prostate cancer. Natl Clin. Pract. Urol. 2(3), 136-142 (2005).
5. Eastham JA: Surgery insight: optimizing open nerve-sparing radical prostatectory techniques for improved outcomes. Natl Clin. Pract. Urol. 4(10), 561-569 (2007).
6. Eton DT, Lepore SJ: Prostate cancer and health-related quality of life: a review of the literature. Psychooncology 11, 307-326 (2002).
7. Zelefsky MJ, Fuks Z, Hunt M et al.: High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. Int. J. Radiat. Oncol. Biol. Phys. 53, 1111-1116 (2002).
8. Chen RC, Clark JA, Manola J, Talcott JA: Treatment 'mismatch' in early prostate cancer: do treatment choices take patient quality of life into account? Cancer 112(1), 61-68 (2008).
9. Holzbeierlein JM, Castle E, Thrasher JB: Complications of androgen deprivation therapy: prevention and treatment. Oncology (Williston Park) 18(3), 303-309; discussion 310 (2004).
10. Herr HW, O'Sullivan M: Quality of life of asymptomatic men with nonmetastatic prostate cancer on androgen deprivation therapy. J. Urol. 163(6), 1743-1746 (2000).
11. Thompson CA, Shanafelt TD, Loprinzi CL: Andropause: symptom management for prostate cancer patients treated with hormonal ablation. Oncologist 8(5), 474-487 (2003).
12. Keating NL, O'Malley AJ, Smith MR: Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J. Clin. Oncol. 24(27), 4448-4456 (2006).
13. D'Amico AV, Denham JW, Crook J et al.: Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J. Clin. Oncol. 25(17), 2420-2425 (2007).
14. Loblaw DA, Virgo KS, Nam R et al.: Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J. Clin. Oncol. 25(12), 1596-1605 (2007).
15. Roth AJ, Kornblith AB, Batel-Copel L et al.: Rapid screening for psychologic distress in men with prostate cancer: a pilot study. Cancer 82, 1904-1908 (1998).
16. Pirl WF, Siegel GI, Goode MJ, Smith MR: Depression in men receiving androgen deprivation therapy for prostate cancer: a pilot study. Psychooncology 11, 518-523 (2002).
17. Litwin MS, Lubeck DP, Henning JM et al.: Differences in urologist and patient assessments of health related quality of life In men with prostate cancer: results of the CaPSURE database. J. Urol. 159, 1988-1992 (1998).
18. Ene KW, Nordberg G, Johansson FG, Sjöström B: Pain, psychological distress and health-related quality of life at baseline and 3 months after radical prostatectory. BMC Nurs. 1, 5-8 (2006).
19. Bokhour BG, Clark JA, Inui TS, Silliman RA, Talcott TA: Sexuality after treatment for early prostate cancer: exploring the meanings of "erectile dysfunction". J. Gen. Intern. Med. 16(10), 649-655 (2001).
20. Penson D, Mclerran D, Feng Z et al.: 5-year urinary and sexual outcomes after radical prostatectomy: results from the Prostate Cancer Outcomes Study. J. Urol. 173(5), 1701-1705 (2005).
21. Schover LR, Fouladi RT, Warneke CL et al.: Seeking help for erectile dysfunction after treatment for prostate cancer? Arch. Sex. Behav. 33(5), 443-454 (2004).
22. Rabbani F, Stapleton AM, Kattan MW, Wheeler TM, Scardino PT: Factors predicting recovery of erections after radical prostatectomy. [see comment]. J. Urol. 164(6), 1929-1934 (2000).
23. Schover LR, Fouladi RT, Warneke CL: Defining sexual outcomes after treatment for localized prostate carcinoma. Cancer 95(8), 1773-1785 (2002).
24. Mulhall JP: Deciphering erectile dysfunction drug trials. J. Urol. 170(2 Pt 1), 353-358 (2003).
25. Dubbelman YD, Dohle GR, Schroder FH: Sexual function before and after radical retropubic prostatectomy: a systematic review of prognostic indicators for a successful outcome. Eur Urol. 50(4), 711-718; discussion 718-720 (2006).
26. Walsh PC: Radical prostatectomy for localized prostate cancer provides durable cancer control with excellent quality of life: a structured debate. J. Urol. 163(6), 1802-1807 (2000).
27. Geary ES, Dendinger TE, Freiha FS, Stamey TA: Nerve sparing radical prostatectomy: a different view. J. Urol. 154(1), 145-149 (1995).
28. Tsujimura A, Matsumiya K, Miyagawa Y et al.: Relation between erectile dysfunction and urinary incontinence after nerve-sparing and non-nerve-sparing radical prostatectomy. Urol. Int. 73(1), 31-35 (2004).
29. Mantz CA, Song P, Farhangi E et al.: Potency probability following conformal megavoltage radiotherapy using conventional doses for localized prostate cancer.Int. J. Radiat. Oncol. Biol. Phys. 37(3), 551-557 (1997).
30. Brandeis JM, Litwin MS, Burnison CM, Reiter RE: Quality of life outcomes after brachytherapy for early stage prostate cancer. J. Urol. 163(3), 851-857 (2000).
31. Huang GJ, Sadetsky N, Carroll P, Penson DF: Predictors of HRQOL during long-term follow-up of men treated for prostate cancer. Prostate Cancer Symposium. Orlando, FL, USA, 22-24 February 2007.
32. Montorsi F, Guazzoni G, Strambi LF et al.: Recovery of spontaneous erectile function after nerve-sparing radical retropubic prostatectomy with and without early intracavernous injections of alprostadil: results of a prospective, randomized trial. [see comment]. J. Urol. 158(4), 1408-1410 (1997).
33. Mulhall JP, Land S, Parker M, Waters WB, Flanigan RC: The use of an erectogenic pharmacotherapy regimen following radical prostatectomy improves recovery of spontaneous erectile function. J. Sex. Med. 2(4), 532-540; discussion 540-542 (2005).
34. Mulhall JP, Slovick R, Hotaling J et al.: Erectile dysfunction after radical prostatectomy: hemodynamic profiles and their correlation with the recovery of erectile function. J. Urol. 167(3), 1371-1375 (2002).
35. McCullough AR: Prevention and management of erectile dysfunction following radical prostatectomy. Urol. Clin. North Am. 28(3), 613-627 (2001).
36. Kava BR, Yang Y, Soloway CT: Efficacy and patient satisfaction associated with penile prosthesis revision surgery. J. Sex. Med. 4(2), 509-518 (2007).
37. Schover LR: Sexuality and fertility after cancer. Hematology Am. Soc. Hematol. Educ. Program 523-527 (2005).
38. Shabsigh R, Klein LT, Seidman S, Kaplan SA, Lehrhoff BJ, Ritter JS: Increased incidence of depressive symptoms in men with erectile dysfunction. Urology 52(5), 848-852 (1998).
39. Araujo A, Durante R, Feldman HA, Goldstein I, McKinlay JB: The relationship between depressive symptoms and male erectile dysfunction: cross-sectional results from the Massachusetts Male Aging Study. Psychosom. Med. 60(4), 458-465 (1998).
40. Nicolosi A, Moreira ED Jr, Villa M, Glasser DB: A population study of the association between sexual function, sexual satisfaction and depressive symptoms in men. J. Affect. Disord. 82(2), 235-243 (2004).
41. Müller MJ, Ruof J, Grar-Morgentern M, Porst H, Benkert O: Quality of partnership in patients with erectile dysfunction after sildenafil treatment. Pharmacopsychiatry 34(3), 91-95 (2001).
42. Riley A, Riley E: Behavioural and clinical findings in couples where the man presents with erectile disorder: a retrospective study. Int. J. Clin. Pract. 54(4), 220-224 (2000).
43. Krahn M, Ritvo P, Irvine J et al.: Patient and community preferences for outcomes in prostate cancer: implications for clinical policy. Med. Care 41(1), 153-164 (2003).
44. Penedo FJ, Molton I, Dahn JR et al.: A randomized clinical trial of group-based cognitive-behavioral stress management in localized prostate cancer: development of stress management skills improves quality of life and benefit finding. Ann. Behav. Med. 31(3), 261-270 (2006).
45. Dorey G: A clinical overview of the treatment of post-prostatectory incontinence. Br. J. Nurs. 16(19), 1194-1199 (2007).
46. Baum NH, Torti DC: Managing hot flashes in men being treated for prostate cancer. Geriatrics 62(11), 18-21 (2007).
47. Barton D, Loprinzi CL: Making sense of the evidence regarding nonhormonal treatments for hot flashes. Clin. J. Oncol. Nurs. 8, 39-42 (2004).
48. Naoe M, Ogawa Y, Shichijo T, Fuji K, Fukagai T, Yoshida H: Pilot evaluation of selective serotonin reuptake inhibitor antidepressants in hot flash patients under androgen-deprivation therapy for prostate cancer. Prostate Cancer Prostatic Dis. 9(3), 275-278 (2006).
49. Lajiness MJ: Megestrol acetate for the treatment of hot flashes in men undergoing hormone ablation therapy or orchiectomy. Urol. Nurs. 27(6), 556-557 (2007).
50. Carlsson S, Aus G, Wessman C, Hugosson J: Anxiety associated with prostate cancer screening with special reference to men with a positive screening test (elevated PSA) - results from a prospective, population-based, randomised study. Eur. J. Cancer 43(14), 2109-2116 (2007).
51. Roth AJ, Rosenfeld B, Kornblith AB et al.: The memorial anxiety scale for prostate cancer; validation of a new scale to measure anxiety in men with prostate cancer. Cancer 97, 2910-2918 (2003).
52. Roth AJ, Kornblith AB, Batel-Copel L et al.: Rapid screening for psychological distress in men with prostate cancer: a pilot study. Cancer 82, 1904-1908 (1998).
53. Nelson CJ, Rosenfeld S, Roth AJ: Coping with your diagnosis and moving forward. In: American Cancer Society's Complete Guide to Prostate Cancer. Bostwick DG, Crawford ED, Higano CS, Roach M (Eds). American Cancer Society Health Promotions, GA, USA, 81-88 (2005)
54. Canada AL, Neese LE, Sui D, Schover LR: Pilot intervention to enhance sexual rehabilitation for couples after treatment for localized prostate carcinoma. Cancer 104(12), 2689-2700 (2005).
55. Boehmer U, Clark JA: Communication about prostate cancer between men and their wives. J. Fam. Pract. 50(3), 226-223 (2001).
56. Kornblith AB, Herr HW, Ofman US et al.: Quality of life of patients with prostate cancer and their spouses: the value of a database in clinical care. Cancer 73, 2791-2802 (1994).